ArticleResearch square2026
Epidemiological and Multi-Omics Investigation of Phytosterol Intake and Type 2 Diabetes Risk.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Objectives: Limited evidence exists on the association between dietary phytosterol intake and the risk of type 2 diabetes (T2D). We aimed to investigate this association and identify the underlying plasma metabolic, metabolomic, and gut microbial features. Methods: We followed 204,633 participants (79% women) from three large US prospective cohorts for up to 36 years. Validated food-frequency questionnaires were used to estimate dietary intake of total phytosterol and three subtypes: β-sitosterol, campesterol, and stigmasterol. We applied Cox proportional hazards models to evaluate their associations with T2D risk. In a subset of 39,879 participants with plasma metabolic biomarkers and 9,528 participants with plasma metabolomics data, we examined the association between phytosterol intake and metabolic biomarkers related to insulinemia, glycemia, lipids, and inflammation, as well as T2D-related metabolomic profiles. Additionally, we explored the gut microbial species and enzymes involved in these associations in a subset of 465 participants with gut microbiome data. Results: During follow-up, we documented 20,708 incident T2D cases. After adjustment for covariates, higher intake of total phytosterol was associated with a lower T2D risk (HR comparing extreme quintiles = 0.87, 95% CI: 0.82, 0.92; P trend<0.001). Similar associations were observed for β-sitosterol (HR=0.86, 95% CI: 0.81, 0.91; P trend<0.001) and campestrol (HR=0.89, 95% CI: 0.84, 0.94; P trend<0.001), but not for stigmasterol.β-sitosterol and campestrol were also associated with favorable plasma metabolic profiles, such as lower levels of C-reactive protein, leptin, and C-peptide, as well as beneficial T2D-relevant metabolomic profiles. Moreover, we identified several gut microbial species, and their enzymes involved in these associations. For example, Conclusions: A higher intake of phytosterols, particularly β-sitosterol and campesterol, was associated with a lower risk of T2D, with consistent findings across epidemiological and multi-omics analyses. These findings support the role of a healthy plant-based dietary pattern rich in phytosterol-containing foods such as whole grains, nuts, seeds, fruits, vegetables, and vegetable oils in lowering T2D risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.